US EditionTransverse Medical completes first patient series involving Point-Guard CEP device - Cardiovascular News
Summary by Cardiovascular News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Transverse Medical completes first patient series involving Point-Guard CEP device - Cardiovascular News
Transverse Medical has announced the completion of the first series of patients under its feasibility clinical study at the Victorian Heart Hospital in Melbourne, Australia. Patients undergoing transcatheter aortic valve implantation (TAVI) procedures were treated using the company’s next-generation Point-Guard cerebral embolic protection (CEP) device, marking what Transverse describes as a “major milestone” in the clinical evaluation of this in…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
